EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) kicked off on Monday, down -3.94% from the previous trading day, before settling in for the closing price of $9.38. Over the past 52 weeks, EYPT has traded in a range of $5.67-$30.99.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 74.19% over the past five years. While this was happening, its average annual earnings per share was recorded -30.66%. With a float of $49.00 million, this company’s outstanding shares have now reached $49.04 million.
Let’s look at the performance matrix of the company that is accounted for 121 employees.
EyePoint Pharmaceuticals Inc (EYPT) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of EyePoint Pharmaceuticals Inc is 5.93%, while institutional ownership is 105.20%. The most recent insider transaction that took place on Jun 03 ’24, was worth 119,705. In this transaction Director of this company sold 11,625 shares at a rate of $10.30, taking the stock ownership to the 3,700 shares. Before that another transaction happened on May 14 ’24, when Company’s Director sold 11,625 for $12.65, making the entire transaction worth $147,045. This insider now owns 5,550 shares in total.
EyePoint Pharmaceuticals Inc (EYPT) Latest Financial update
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -0.61 earnings per share (EPS), lower than consensus estimate (set at 0.6) by -1.21. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.66% per share during the next fiscal year.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Trading Performance Indicators
Take a look at EyePoint Pharmaceuticals Inc’s (EYPT) current performance indicators. Last quarter, stock had a quick ratio of 5.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.83, a number that is poised to hit -0.54 in the next quarter and is forecasted to reach -3.10 in one year’s time.
Technical Analysis of EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) saw its 5-day average volume 0.62 million, a negative change from its year-to-date volume of 1.09 million. As of the previous 9 days, the stock’s Stochastic %D was 34.06%. Additionally, its Average True Range was 0.78.
During the past 100 days, EyePoint Pharmaceuticals Inc’s (EYPT) raw stochastic average was set at 1.12%, which indicates a significant decrease from 10.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.43% in the past 14 days, which was lower than the 109.58% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.21, while its 200-day Moving Average is $16.13. Nevertheless, the first resistance level for the watch stands at $9.28 in the near term. At $9.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.70. If the price goes on to break the first support level at $8.86, it is likely to go to the next support level at $8.71. The third support level lies at $8.44 if the price breaches the second support level.
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) Key Stats
The company with the Market Capitalisation of 469.24 million has total of 52,084K Shares Outstanding. Its annual sales at the moment are 46,020 K in contrast with the sum of -70,800 K annual income. Company’s last quarter sales were recorded 11,680 K and last quarter income was -29,280 K.
